Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812
Schizophrenia
About this trial
This is an interventional diagnostic trial for Schizophrenia focused on measuring safety, pharmacokinetics,
Eligibility Criteria
Inclusion criteria:
- Healthy
- Body Weight >/=50kg and BMI 18.5-29.9 kg/m2 inclusive
- Normal 12-lead ECG, physical examination and lab screen
Exclusion criteria:
- A history of psychiatric illness,
- A history or presence gastro-intestinal,
- A hepatic or renal disease or orthostatic hypotension.
Sites / Locations
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Subjects receiving ketoconazole for 8 days
Subjects receiving ketoconazole for 14 days
In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.